Actively Recruiting
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Led by Peking University Cancer Hospital & Institute · Updated on 2025-03-25
42
Participants Needed
3
Research Sites
233 weeks
Total Duration
On this page
Sponsors
P
Peking University Cancer Hospital & Institute
Lead Sponsor
N
Nanjing Legend Biotech Co.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.
CONDITIONS
Official Title
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects voluntarily participate in clinical research
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) score 0-1
- Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or indolent lymphoma to diffuse large B-cell lymphoma, CD20 positive
- At least one measurable tumor lesion per Lugano 2014 criteria
- Expected survival of at least 3 months
- Clinical laboratory values meet screening criteria
- Use of effective contraception
You will not qualify if you...
- Prior antitumor therapy without sufficient washout period
- Previous treatment with allogeneic cell and gene therapy such as CAR-T, except if CAR-positive cells and transgenes are below detection
- Previous allogeneic hematopoietic stem cell transplantation
- Previous gene therapy
- Donor specific antibody (DSA) positive
- Severe underlying diseases
- Positive for hepatitis B virus DNA, hepatitis C virus RNA, or HIV antibody
- Other serious medical conditions limiting study participation as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Beijing GoBroad Boren Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
2
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
3
Henan Cancer Hospital
Zhengzhou, China
Actively Recruiting
Research Team
Y
Yuqin Song
CONTACT
Y
Yan Xie
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here